retatrutide phase 2 trial type 2 diabetes weight loss 2024 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide improves blood sugar and

Semaglutide May Be Considered When A patient is an appropriate candidate for GLP-1 therapy and needs medical support for appetite, weight, blood sugar, and cardiometabolic risk

A.BoykoE

FDA-approved drugs undergo a long and rigorous process of clinical trials to prove their safety, effectiveness, and quality before they can be marketed to the public. Compounded drugs, even from 503B facilities, do not go through this same pre-market approval process

GLP-1 receptor agonists offer a promising solution for T2DM management, aiding glycemic control while addressing the weight management challenges associated with diabetes